Ophthotech (OPHT) Upgraded to C at TheStreet
Other equities analysts have also recently issued research reports about the stock. ValuEngine raised shares of Ophthotech from a hold rating to a buy rating in a research note on Monday, October 2nd. Stifel Nicolaus reaffirmed a hold rating and set a $4.00 price objective on shares of Ophthotech in a research note on Thursday, September 21st. Finally, Zacks Investment Research raised shares of Ophthotech from a hold rating to a strong-buy rating and set a $3.25 price objective for the company in a research note on Monday, November 13th. Twelve research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $8.31.
Ophthotech (NASDAQ OPHT) traded up $0.06 on Thursday, hitting $3.20. 663,047 shares of the stock traded hands, compared to its average volume of 1,042,381. The stock has a market capitalization of $113.16, a P/E ratio of 2.00 and a beta of 1.56. Ophthotech has a 52-week low of $2.24 and a 52-week high of $40.34.
A number of large investors have recently modified their holdings of OPHT. First Manhattan Co. purchased a new position in Ophthotech during the third quarter valued at approximately $1,201,000. Tamarack Advisers LP grew its stake in Ophthotech by 32.7% during the second quarter. Tamarack Advisers LP now owns 625,000 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 153,851 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Ophthotech by 28.1% during the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after acquiring an additional 143,349 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in Ophthotech by 97.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 260,600 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 128,900 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in Ophthotech in the 2nd quarter worth approximately $269,000. 62.57% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Ophthotech (OPHT) Upgraded to C at TheStreet” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/12/02/ophthotech-opht-upgraded-to-c-at-thestreet.html.
Ophthotech Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp and related companies with MarketBeat.com's FREE daily email newsletter.